Concert Pharmaceuticals, Inc. (CNCE) financial statements (2020 and earlier)

Company profile

Business Address 65 HAYDEN AVENUE
LEXINGTON, MA 02421
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1221532039614279
Cash and cash equivalents331828419313
Short-term investments94143176565066
Other undisclosed cash, cash equivalents, and short-term investments(5)(8)000(0)
Receivables010001
Contract with customer, asset 16
Other undisclosed current assets9102221
Total current assets:1311802069814482
Noncurrent Assets
Operating lease, right-of-use asset9
Property, plant and equipment892222
Restricted cash and investments112000
Other noncurrent assets0 0000
Other undisclosed noncurrent assets222   
Total noncurrent assets:21126333
TOTAL ASSETS:15219321210014784
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities464343
Accounts payable111111
Accrued liabilities111111
Employee-related liabilities233232
Taxes payable 00 0 
Deferred revenue8
Debt0    7
Deferred revenue and credits2116
Contract with customer, liability1
Other undisclosed current liabilities211112
Total current liabilities:14966719
Noncurrent Liabilities
Long-term debt and lease obligation16     
Operating lease, liability16
Liabilities, other than long-term debt312991011
Deferred revenue and credits991011
Deferred revenue3
Contract with customer, liability9
Deferred rent credit 3
Other undisclosed noncurrent liabilities 4    
Total noncurrent liabilities:1916991011
Total liabilities:332515151630
Stockholders' equity
Stockholders' equity attributable to parent1191681968613155
Common stock000000
Additional paid in capital293284273257252200
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0)
Accumulated deficit(174)(117)(76)(172)(121)(145)
Total stockholders' equity:1191681968613155
TOTAL LIABILITIES AND EQUITY:15219321210014784

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net1440577
Gross profit:0111440679
Operating expenses(79)(66)(51)(51)(42)(39)
Other undisclosed operating income1     
Operating income (loss):(78)(56)93(51)25(31)
Nonoperating income (expense)3340(0)(1)
Investment income, nonoperating231000
Other nonoperating income (expense) 03 (0)(1)
Interest and debt expense  (1) (0)(0)
Income (loss) from continuing operations before equity method investments, income taxes:(75)(53)95(51)25(32)
Other undisclosed income from continuing operations before income taxes    0 
Income (loss) from continuing operations before income taxes:(75)(53)95(51)25(32)
Income tax expense (benefit)(0)(0)0 (0) 
Net income (loss):(75)(53)96(51)24(32)
Other undisclosed net income (loss) attributable to parent(4)(3)   0
Net income (loss) attributable to parent:(79)(56)96(51)24(32)
Preferred stock dividends and other adjustments     (0)
Undistributed earnings (loss) allocated to participating securities, basic  (0)
Net income (loss) available to common stockholders, basic:(79)(56)95(51)24(32)
Other undisclosed net income available to common stockholders, diluted  0   
Net income (loss) available to common stockholders, diluted:(79)(56)95(51)24(32)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(75)(53)96(51)24(32)
Other comprehensive income (loss)  95(51)24(32)
Comprehensive income (loss):(75)(53)191(101)48(64)
Other undisclosed comprehensive loss, net of tax, attributable to parent(3)(3)    
Comprehensive income (loss), net of tax, attributable to parent:(78)(56)191(101)48(64)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: